Hookipa Pharma Inc. Stock News

NEW YORK , Feb. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FTK, HOOK, PHUN, ZOM, and BTU. … Full story available on Benzinga.com

Low float penny stocks to add to your watch list right now. The post Best Penny Stocks To Buy?

US stocks traded lower midway through trading on Wednesday ahead of the release of Fed minutes. The Dow traded down 0.59% to 34,783.36 while the NASDAQ fell 0.92% to 14,009.57. The S&P also fell, dropping, 0.52% to 4,447.84. Check out this: Insiders Buy More Than $18M Of 4 Stocks Leading and Lagging Sectors Energy shares climbed 1.7% on Wednesday. Meanwhile, top gainers in the sector included NextDecade Corporation (NASDAQ: NEXT ), up 9% and Crescent Energy Company (NYSE: CRGY ) up 11%. In trading on Wednesday, information technology shares tumbled by 1.2%. Top Headline US crude-oil inventories gained 1.121 million barrels last week, the Energy Information Administration said. Analysts, however, were expecting for a 1.769-million-barrel decline in inventories. Equities Trading UP Upstart Holdings, Inc.. (NASDAQ: UPST ) shares shot up 36% to $148.09 after the company reported better-than-expected Q4 results and issued sales guidance above estimates. The company also announced a $400 million buyback.

What you need to know about trading penny stocks on February 16th The post Trading Penny Stocks? Top Stock Market News for February 16th, 2022 appeared first on Penny Stocks to Buy, Picks, News and I

NEW YORK , Feb. 16, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HOOK, CRSR, VCSA, IS, and JOBY. … Full story available on Benzinga.com

Hookipa Pharma Inc (NASDAQ: HOOK) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD) for arenaviral immunotherapy as a component of a potential funct

Hookipa Pharma Inc (NASDAQ: HOOK ) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD ) for arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV). In April 2018, Gilead licensed exclusive rights to Hookipa''s arenaviral platform to develop immunotherapies for HIV and hepatitis B virus (HBV). The companies agreed to … Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following Amended HIV Study Agreem

What you need to know about trading penny stocks on February 16th The post Trading Penny Stocks? Top Stock Market News for February 16th, 2022 appeared first on Penny Stocks to Buy, Picks, News and In

Hookipa Pharma Inc (NASDAQ: HOOK) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD) for arenaviral immunotherapy as a component of a potential funct

Gainers: HOOKIPA Pharma HOOK +54%. Upstart Holdings UPST +23%

HOOKIPA (HOOK) shares are 45% higher in after-hours trading after it amended an agreement with Gilead (GILD) for the development of an arenaviral immunotherapy for HIV.

NEW YORK and VIENNA, Austria, Feb. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary are

HOOKIPA to develop arenaviral-based therapeutic for HIV through Phase 1b clinical trial completion; Gilead has exclusive rights for further program development thereafter Financial terms include $15 million initiation fee and $35 million equity commitment NEW YORK and VIENNA, Austria, Feb. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK , ‘HOOKIPA'')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced it has entered into an amended and restated collaboration and license agreement with Gilead to advance the development of a novel arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV). In April 2018, Gilead licensed exclusive rights to HOOKIPA''s versatile arenaviral platform to develop immunotherapies for HIV and hepatitis B virus (HBV). Under those terms, the companies agreed to collaborate through a joint research phase, after which time Gilead had rights for further development.

The U.S. Food and Drug Administration granted fast track designation to HOOKIPA Pharma''s (HOOK) immunotherapy candidates, single-vector HB-201 and alternating 2-vector HB-202/HB-201,